Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : NSDQ)
 
 • Company Description   
Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

Number of Employees: 21

 
 • Price / Volume Information   
Yesterday's Closing Price: $133.24 Daily Weekly Monthly
20 Day Moving Average: 1,487,344 shares
Shares Outstanding: 0.56 (millions)
Market Capitalization: $74.84 (millions)
Beta: 2.47
52 Week High: $240.00
52 Week Low: $0.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1,619.23% 1,571.90%
12 Week 1,510.99% 1,403.71%
Year To Date 321.93% 259.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
611 GATEWAY BOULEVARD SUITE 740
-
SOUTH SAN FRANCISCO,CA 94080
USA		 ph: 415-655-4168
fax: -		 investors@sprucebio.com http://www.sprucebiosciences.com
 
 • General Corporate Information   
Officers
Javier Szwarcberg - Chief Executive Officer
Michael Grey - Executive Chairman
Samir Gharib - President and Chief Financial Officer
Tiba Aynechi - Director
Percival Barretto-Ko - Director

Peer Information
Spruce Biosciences, Inc. (CORR.)
Spruce Biosciences, Inc. (RSPI)
Spruce Biosciences, Inc. (CGXP)
Spruce Biosciences, Inc. (BGEN)
Spruce Biosciences, Inc. (GTBP)
Spruce Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 85209E208
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/10/25
Share - Related Items
Shares Outstanding: 0.56
Most Recent Split Date: 8.00 (0.01:1)
Beta: 2.47
Market Capitalization: $74.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-6.85 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/10/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.68
Price/Cash Flow: -
Price / Sales: 15.24
EPS Growth
vs. Year Ago Period: 78.84%
vs. Previous Quarter: 85.45%
Sales Growth
vs. Year Ago Period: -75.86%
vs. Previous Quarter: 15.78%
ROE
09/30/25 - -
06/30/25 - -177.45
03/31/25 - -143.15
ROA
09/30/25 - -
06/30/25 - -118.06
03/31/25 - -101.99
Current Ratio
09/30/25 - -
06/30/25 - 2.60
03/31/25 - 1.95
Quick Ratio
09/30/25 - -
06/30/25 - 2.60
03/31/25 - 1.95
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -3,721.17
03/31/25 - -1,906.22
Book Value
09/30/25 - -
06/30/25 - 23.47
03/31/25 - 27.28
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©